Company profile
Quasi Vivo | The researchers choice for cell culture| Kirkstall Ltd
Quasi Vivo organ-on-a-chip technology for more human relevant research. View our range of products and applications.
Updated 06 Jun 2026 16:52
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNTYyMTQ1N2FkaXF6a2N4
Published 13 Sep 2024 13:37
Company registered at Companies House
1 Nov 2017 to 31 Jul 2018
To develop and launch of a new-to-market 'QV CardioBox, which provides an off-the-shelf solution for in-vitro tests for the monitoring of safety and/or efficacy of compounds in the cardiovascular system.
1 Nov 2014 to 31 Jan 2016
The blood–brain barrier (BBB) is composed of different specialised cell types and regulates exchange of substances between the blood and the brain. There are a large number of diseases including stroke, brain trauma and tumours in which the permeability of the BBB is increased. Conversely, many drugs are unable to cross the BBB to reach the brain making t...
1 Oct 2014 to 30 Sep 2016
Cardiovascular diseases account for more than 150,000 annual deaths in UK, affect more than 5 million people and cost more than £30bn a year to treat. To tackle this problem, drug companies and academics are trying to find new ways to expand our understanding of the causes of cardiovascular disease, and develop new ways of treating them. Usually, this res...
1 Sep 2012 to 30 Nov 2014
Awaiting Public Summary
1 May 2010 to 30 Nov 2012
Kirkstall is developing in-vitro cell culture systems. It recently completed a GRD Research project which established the technical and commercial feasibility of using technology licensed from the University of Pisa, to detect chemical toxicity. The GRD project also enabled the company to transfer the technology from Pisa into its laboratories in Sheffiel...
